Market data including bonds and fuel prices
The fun and games in this innovative and rapidly changing sector will be well worth watching
Upgrade of outdated tobacco law on the way at last
The premier announced her cabinet after a meeting with the ANC’s deployment committee and its alliance partners
Business Day TV speaks to African Rail Industry Association CEO Mesela Nhlapo
Credit bureau sees more defaults ahead as central bank increases interest rates
The improved sentiment is a result of increased merchandise export and import volumes and more new vehicles sold, Sacci report says
The monetary policy committee increases the key policy rate to 6% from 5%
Top swimmers have a rivalry that could develop into one of SA sport’s greatestt
Former world boxing champion furious over unauthorised production
Namibia has warned that more than 268,000 doses of AstraZeneca and Pfizer Covid-19 vaccines are at risk of being destroyed, some as early as next week, due to a slow uptake by citizens.
Ben Nangombe, executive director in the health ministry, said on Thursday that 52,261 AstraZeneca vaccines will expire next Tuesday, while 215,996 Pfizer shots will be destroyed in January and February if they find no takers as vaccine hesitancy rises.
Namibia, which has started vaccinating people aged 12 to 17 with the Pfizer vaccine after the World Health Organisation (WHO) said on November 15 that it is suitable for people in that age group, has 809,414 doses available nationally.
It recorded 15 new cases on Tuesday to bring the number of active cases to 85 compared with a peak of 2,547 cases in a single day on June 24.
Only 298,503, or 20%, of an estimated eligible population of 1.5-million have been fully vaccinated in Namibia, with the Chinese-made Sinopharm vaccine the most used after 145,483 people received two doses since the country’s vaccination programme started in March.
The Russian-made Sputnik V vaccine has been used the least, with only 71 people fully vaccinated before its rollout was suspended on October 23, days after the drugs regulator in neighbouring SA flagged concerns about its safety for people at risk of HIV.
The SA Health Products Regulatory Authority decided against approving an emergency use application for Sputnik V after some studies suggested vaccines using the Adenovirus Type 5 vector, which Sputnik V does, can lead to higher susceptibility to HIV in men.
SA and Namibia have high HIV prevalence rates.
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.